Pfizer Inc. has secured an exclusive global licensing agreement with 3SBio, Inc., a leading Chinese biopharma, for SSGJ-707.

While Bourla has insisted growing the payout is a high priority for the company, with a near-100% FCF payout ratio, it may not be able to grow the dividend as promised. Pfizer also has no plans to ...

Despite trading near decade-low valuations, Pfizer PFE is strategically repositioning itself for substantial long-term growth through its oncology transformation, particularly via the Seagen ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Pharmaceutical stocks, including Pfizer (NYSE: PFE ... with annual sales surging to over $100 billion in 2022 from just $42 billion in 2020, driven by unprecedented demand for its vaccines.

Does this mean Pfizer's dividend is 100% safe? Unfortunately, no. The company faces several uncertainties that could make it difficult to maintain and grow the dividend. The perennial challenge ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...

The GOP-led House Judiciary Committee is requesting records from Pfizer’s CEO and an interview with a former company executive to investigate an allegation that clinical testing related to the ...